NCT01487629

Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema

Bevacizumab Versus Ranibizumab for Refractory Diabetic Macular Edema

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 53 (actual)
• Sponsor: University of Sao Paulo · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the morphological and visual acuity outcomes associated with 1.5 mg bevacizumab versus 0.5 ranibizumab intravitreal injections for treatment of diabetic macular edema.

Conditions

• Diabetic Retinopathy
• Macular Edema

Interventions

Type	Name	Description
DRUG	Bevacizumab	Bevacizumab, 1.5 mg, intravitreal, throughout the study
DRUG	Ranibizumab	Ranibizumab, 0.5 mg, intravitreal, throughout the study

Timeline

• Start date: 2010-04-01
• Primary completion: 2012-09-01
• Completion: 2012-09-01
• First posted: 2011-12-07
• Last updated: 2011-12-13

Locations

1 site across 1 country: Brazil